# An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study

> **NCT02990858** · PHASE2,PHASE3 · TERMINATED · sponsor: **CytoDyn, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** PRO 140

## Key facts

- **NCT ID:** NCT02990858
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-03
- **Primary completion:** 2022-06
- **Final completion:** 2022-07-10
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02990858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02990858, "An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02990858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*